



Intended Result	Your Report	Your Score
Specimen 8270 Median concentration 3.95 log copies/mL	5340 IU/mL (3.73 log copies/mL)	
Specimen 8271 Median concentration 3.65 log copies/mL	3770 IU/mL (3.58 log copies/mL)	
Average of the median log differences between specimens 8270 and 8271 is 0.30 log copies/mL	Calculated log difference is 0.15 log copies/mL	2

Cumulative score information
 Total number of specimens sent to you for **UK NEQAS for CMV DNA quantification** over the last 3 distributions is 6
 For these distributions specimen numbers 7628 7873 8270 have been analysed and scored.
 Number of reports analysed 3
 Number of specimens reported as not examined (not scored) 0
 Number of specimens received too late for analysis (not scored) 0
 Number of specimens for which no report was received (not scored) 0
 Your cumulative score for these specimens was 6 out of a possible total of 6
 The mean score calculated from the reports returned by **UK** laboratories was 5.85 with a standard error of 1.09.

Performance rating
 Your performance rating for **UK NEQAS for CMV DNA quantification** (i.e. the number of standard errors by which your cumulative score lies above or below the mean) for **UK** laboratories is 0.13. A performance rating of more than 1.96 standard errors below the mean indicates possible poor performance.
 Please note your performance rating may alter if other participants' results are amended.
 No score penalty is incurred for non return of reports. However non return of results may be used as a measure of poor performance.



Comments: A total of 104 sets of specimens were distributed for testing with 94 participants returning results within the specified period.

Please see pages 3-4 for further comments about this distribution and results from participants who reported in IU/mL.

Participants are still reporting in copies/mL, this report presents the results in copies/mL. Participants who are reporting their results in IU/mL can see their results in IU/mL and also in log copies/mL. Please make sure that you provided us with the correct conversion factor.

Turn around time: Time taken to report your results was 0-days. This is provided for your own use and does not form part of your performance assessment.

Acknowledgements:
 We thank colleagues at UKHSA Birmingham and the Royal Infirmary of Edinburgh for their kind assistance with pre-distribution testing.

Enquiries: Pre-distribution test results are available should you experience a technical failure and wish to discuss the results. Written enquiries about this distribution should be addressed to Dr Sanjiv Rughooputh at organiser@ukneqasmicro.org.uk.

For repeat specimens in case of an EQA failure investigation, please request using the web form at <https://ukneqasmicro.org.uk/participant-info/order-repeat-specimens/>.


Report authorised by: Dr Sanjiv Rughooputh, Scheme Organiser.



A pair of specimens of freeze dried plasma was dispatched with a request for the quantification of CMV DNA. Specimen 8270 and 8271 consisted of CMV at a concentration of 6.53 log copies/mL diluted 1:1000 and 1:2000, respectively, in CMV antibody negative plasma. CMV strain origin: clinical isolate from a neonate urine.

Specimen : 8270

	n (UK)	range	median	5%-95%
All methods	94 (27)	1.31-6.22	3.95	3.43-4.47
Abbott Real-Time	3 (1)	3.88-4.10	4.02	3.89-4.09
Abbott: Alinity m	8 (4)	3.66-4.17	4.04	3.73-4.17
Altona: RealStar	6 (2)	3.96-4.56	4.43	4.04-4.54
Argene	3 (1)	3.58-3.93	3.85	3.61-3.92
ELITech: ELITe InGenius	7 (1)	3.65-4.48	4.38	3.81-4.47
ELITech: ELITe MGB	16 (2)	3.23-4.40	3.96	3.49-4.36
In house	2 (2)	3.73-4.22		
Qiagen: Artus	5 (1)	3.48-3.98	3.97	3.53-3.98
Real-Time Multiplex	5 (4)	3.44-5.14	4.27	3.57-5.10
Real-Time Single target	5 (2)	3.23-4.27	4.08	3.40-4.26
Roche: Cobas 6800/8800	16 (3)	3.57-4.18	3.66	3.59-3.89
Sentosa SX CMV Quant	2 (2)	3.86-4.00		




Your result :
3.73 log copies/mL

Method median concentration :
3.98 log copies/mL

Median concentration :
3.95 log copies/mL

Specimen : 8271

	n (UK)	range	median	5%-95%
All methods	93 (27)	1.39-5.85	3.65	3.23-4.20
Abbott Real-Time	3 (1)	3.51-3.86	3.79	3.54-3.85
Abbott: Alinity m	8 (4)	3.52-4.01	3.74	3.54-3.99
Altona: RealStar	6 (2)	3.61-4.22	4.16	3.72-4.21
Argene	3 (1)	3.07-3.40	3.33	3.09-3.39
ELITech: ELITe InGenius	7 (1)	3.73-4.08	4.02	3.79-4.08
ELITech: ELITe MGB	16 (2)	2.86-4.27	3.64	3.11-4.08
In house	2 (2)	3.58-3.90		
NeuMoDx CMV Quant	2 (1)	3.38-3.73		
Qiagen: Artus	5 (1)	3.25-3.79	3.61	3.29-3.78
Real-Time Multiplex	5 (4)	3.10-5.00	3.90	3.25-4.88
Real-Time Single target	5 (2)	3.26-4.08	3.90	3.37-4.05
Roche: Cobas 6800/8800	16 (3)	3.26-3.83	3.38	3.27-3.57



Your result :
3.58 log copies/mL


Method median concentration :
3.74 log copies/mL

Median concentration :
3.65 log copies/mL

Intended result : -0.20 to 0.80 log copies/mL
(average median of the reported differences in concentration between specimen 8270 and 8271 +/- 0.5 log copies/mL, uncertainty of the median 0.014)

Difference in concentration between specimen 8270 and 8271 expressed in log copies/mL :

	n (UK)	range	av. median	5%-95%
All methods	93 (27)	-0.08-0.60	0.30	0.12-0.43
Abbott Real-Time	3 (1)	0.22-0.37	0.24	0.23-0.36
Abbott: Alinity m	8 (4)	0.14-0.38	0.24	0.15-0.35
Altona: RealStar	6 (2)	0.21-0.35	0.30	0.22-0.35
Argene : Biosoft	3 (1)	0.45-0.60	0.51	0.46-0.59
ELITech: ELITe InGenius	7 (1)	-0.08-0.44	0.30	0.02-0.43
ELITech: ELITe MGB	16 (2)	0.14-0.38	0.31	0.22-0.37
In house	2 (2)	0.15-0.32		
Qiagen: Artus	5 (1)	0.18-0.37	0.26	0.19-0.35
Real-Time Multiplex	5 (4)	0.14-0.50	0.34	0.15-0.48
Real-Time Single target	5 (2)	-0.03-0.36	0.23	-0.02-0.35
Roche: Cobas 6800/8800	16 (3)	0.21-0.41	0.29	0.21-0.40
Sentosa SX CMV Quant	2 (2)	0.24-0.28		



Your result :
Difference in conc. is 0.15 log copies/mL

Your score : 2

Overall results	UK	All	Score
Median			
+/- 0.5 log	27	93	2
+/- >0.5 to 0.75 log	0	0	1
+/- >0.75 to 1.0 log	0	0	0
+/- >1.0 log	0	0	-1
One incorrect	0	1	0
Total	27	94	
%Correct	100.0	98.9	



Comments on distribution 5521

Overall performance in this distribution was excellent with 98.9% of participants reporting the intended results. This performance was an improvement of 2.1% over previous distribution 5393, where the performance rate was 96.8%.

Return rate for this distribution was very good, with 90.4% of participants returning their results within the specified period. Compared to the previous distribution (5393) where 94.1% of participants returned results, this is a decline of 3.7% in the participation rate.

Specimens 8270 and 8271 were prepared from a single neonate urine sample diluted 1000 and 2000 times, respectively, in plasma negative for antibodies against CMV. The estimated viral loads of specimens 8270 and 8271 were 3.53 log copies/mL and 3.23 log copies/mL, respectively, with a difference in concentration of 0.3 log copies/mL between the specimen pair. The specimens were subsequently freeze dried.

Of the 94 participants who returned results, 98.9% (93) reported a difference in concentration within +/- 0.5 log copies/mL of the median reported difference in concentration and received the full score of 2.

As there were no pre-distribution issues, this distribution has been scored.

Participants who did not obtain the intended results are requested to investigate and report the plausible root cause by completing an incident review form (IRF) online within 30 days of this report being published.

Non return of results without a valid reason is considered as poor performance and should also be reported in a similar manner.

IRFs are taken into considerations when poor performance analysis is carried out for the National Quality Assurance Advisory Panel (NQAAP).

IRFs can be completed on the following link: <https://ukneqasmicro.org.uk/incident-review-form/>



Summary of the results reported in IU/mL

Amplification method	8270 (Log IU/mL)	8271 (Log IU/mL)	log difference
Abbott Real-Time	3.65	3.39	0.26
Abbott Real-Time	3.82	3.60	0.22
Abbott Real-Time	3.88	3.51	0.37
Abbott: Alinity m	3.90	3.67	0.24
Abbott: Alinity m	4.03	3.74	0.29
Abbott: Alinity m	3.94	3.78	0.16
Abbott: Alinity m	3.92	3.70	0.22
Abbott: Alinity m	3.95	3.65	0.30
Abbott: Alinity m	4.17	3.79	0.38
Abbott: Alinity m	4.13	3.86	0.26
Roche: Cobas 4800	3.93	3.76	0.18
Roche: Cobas 6800/8800	3.51	3.29	0.22
Roche: Cobas 6800/8800	3.67	3.26	0.41
Roche: Cobas 6800/8800	3.44	3.22	0.22
Roche: Cobas 6800/8800	3.62	3.34	0.28
Roche: Cobas 6800/8800	3.70	3.49	0.21
Roche: Cobas 6800/8800	3.65	3.40	0.25
Roche: Cobas 6800/8800	3.68	3.39	0.29
Roche: Cobas 6800/8800	3.72	3.34	0.38
Roche: Cobas 6800/8800	3.57	3.27	0.30
Roche: Cobas 6800/8800	3.75	3.35	0.40
Roche: Cobas 6800/8800	3.56	3.35	0.21
Roche: Cobas 6800/8800	4.22	3.87	0.36
Roche: Cobas 6800/8800	3.66	3.36	0.29
In house	3.57	3.30	0.27
Real-Time Single target	3.73	3.58	0.15
Real-Time Single target	3.39	3.03	0.36
Real-Time Single target	4.22	3.94	0.28
Real-Time Single target	4.04	4.04	0.00
Real-Time Multiplex	3.23	3.26	-0.03
Real-Time Multiplex	4.10	3.71	0.39
Real-Time Multiplex	4.09	3.90	0.19
Qiagen: Artus	3.20	2.86	0.34
Qiagen: Rotor-Gene	3.84	3.67	0.18
NeuMoDx CMV Quant	4.18	3.78	0.40
NeuMoDx CMV Quant	3.76	3.49	0.27
Altona: RealStar	3.71	3.38	0.33
Altona: RealStar	4.26	3.91	0.35
Altona: RealStar	4.47	4.16	0.31
Altona: RealStar	4.56	4.22	0.34
ELITech: ELITe MGB	4.45	4.15	0.30
ELITech: ELITe MGB	3.77	3.47	0.30
ELITech: ELITe MGB	3.72	3.37	0.36
ELITech: ELITe MGB	4.36	4.04	0.32
ELITech: ELITe MGB	4.10	3.72	0.38
ELITech: ELITe MGB	3.75	3.38	0.37
ELITech: ELITe MGB	4.26	4.00	0.26
ELITech: ELITe MGB	3.96	3.70	0.26
ELITech: ELITe InGenius	4.11	3.77	0.34
Sentosa SX CMV Quant	3.65	3.73	-0.08
Sentosa SX CMV Quant	3.78	3.55	0.24
Median log IU/mL			0.29

End of report

